Vaccination, Hematologic Malignancy, Solid Tumor, Childhood
Conditions
Keywords
Vaccination, Childhood, Hematologic Malignancy, Solid Tumor, Immune Deficiency
Brief summary
The purpose of this study is to study on compliance, safety and effectivity of vaccination for children with hematologic malignancies or solid tumors and their parents.
Detailed description
Children with hematologic malignancies or solid tumors are all facing with immune deficiency due to the disease, the chemotherapy, the hematopoietic stem cell transplantation or the splenectomy, which greatly increases their chance to get infectious diseases. In this study, we will assess the compliance of children with hematologic malignancies or solid tumors and their parents to accept vaccination after finishing treatments, follow up with untoward effect questionnaires to assess the safety, obtain the serum of children patients to test antibody titers and assess the effectivity, provide clues for the study of vaccination in children with hematologic malignancies or solid tumors and provide a scientific basis for the formulation and reunification of vaccination programs.
Interventions
BIOLOGICALVaccination
Patients with higher antibody titers will accept vaccination. There are two vaccines provided in this study: hepatitis B vaccine measles-rubella combined vaccine
OTHERNo Vaccination
Patients with higher antibody titers will NOT accept vaccination. But we will keep monitoring their antibody titers.
Sponsors
Shanghai Pudong District Center for Disease Control and Prevention
Children's Cancer Group, China
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No
Inclusion criteria
1. Children patients(≤18 years) who accepted chemotherapy, hematopoietic stem cell transplantation or splenectomy since our study started. 2. No history of hepatitis B and measles, do not suffer from other diseases that affect immune function and allergic diseases.
Exclusion criteria
1. Children patients who did not reach clinical remission after treatment, critically ill or eventually died. 2. Patients who used monoclonal antibodies, especially anti-tumor necrosis factors. 3. Intermittent or low-dose chemotherapy or other immunosuppressive drugs users.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of parents of children willing to be vaccinated after receiving relevant knowledge propagation | 2 years |
| Number of participants with vaccination-related adverse events | 2 years |
| The level of serum antibody increased after vaccination | 2 years |
Countries
China
Contacts
Primary ContactYi-Jin Gao, MD
Backup ContactXing-Wei Wang, MD
Outcome results
None listed